Cholesterol guidelines just had their biggest update in years.
The 2026 ACC/AHA Guideline on the Management of Dyslipidemia officially added ApoB and Lp(a) to how cardiovascular risk should be assessed. These are markers that a standard cholesterol panel doesn’t include, which means most people are still having a 2015 version of this conversation with their GP.
That matters. But there’s another gap worth raising: one that rarely comes up in a standard review at all.
What changed in the 2026 cholesterol guidelines
For years, LDL cholesterol has been the headline number. High LDL, reduce it. That’s often the extent of the clinical conversation.
The updated guidelines shift that. ApoB: a marker that reflects the number of cholesterol-carrying particles in your blood, not just their total volume. Is now part of how risk should be assessed. So is Lp(a), a genetically determined lipoprotein that standard panels don’t measure and that carries its own independent cardiovascular risk.
This is significant because two people can have the same LDL number and very different actual risk profiles. Particle number and particle type matter. Total cholesterol as a single figure tells you very little that’s clinically actionable.
These guidelines are American, but UK clinical practice tends to follow the same direction of travel. Worth knowing.
The part that almost never comes up: your brain
Most cholesterol conversations go cardiac. Rarely cognitive.
Around 25% of the body’s total cholesterol lives in the brain. It’s not a risk factor there; it’s structural. It supports the myelin sheath, the insulation around nerve fibres that keeps your thinking sharp, fast, and connected.
The fats in your diet affect how well your brain cells communicate, how much inflammation your brain is managing, and how your cognitive function holds up over time. That’s not a fringe idea, it’s increasingly well-supported in the research on metabolic brain health.
But it’s not a conversation that tends to happen in a standard ten-minute cholesterol review.
What a more complete picture actually looks like
If you’ve ever left a GP appointment with “reduce it” as your only takeaway, there’s likely more in your panel worth discussing. A more complete assessment of metabolic and cognitive risk would include:
- ApoB: particle number, not just volume
- Lp(a): genetically determined, independent risk marker
- Triglyceride to HDL ratio: one of the more sensitive markers of how your body is handling carbohydrates day to day
- Fasting glucose and insulin: the metabolic picture underneath
- Dietary fat composition: the type of fat in your diet, not just the quantity, affects both cardiovascular and cognitive health
This isn’t about alarm. It’s about having a fuller conversation — one that connects the metabolic to the cognitive, and gives you something more useful to work with than a single number.
What this means in practice
Knowing what to ask for at your next appointment is a reasonable starting point. So is understanding how your diet is affecting not just your heart markers but your brain function day to day: energy, clarity, how you’re thinking at 3pm.
That’s the kind of work I do with clients: connecting the panel to the pattern, and building a nutritional approach that supports both metabolic health and cognitive performance long-term.
If you’d like to get a clearer picture of where you currently sit, my free Metabolic Check-In is a useful place to start.
Source: 2026 ACC/AHA Guideline on the Management of Dyslipidemia